Eliminating Cancer Stem Cells in CML with Combination Transcriptional Therapy

Cell Stem Cell. 2016 Jul 7;19(1):6-8. doi: 10.1016/j.stem.2016.06.005.

Abstract

Leukemia stem cells (LSCs) are resistant to current therapies used to treat chronic myeloid leukemia (CML). Abraham et al. (2016) have identified a molecular network critical for CML LSC survival and propose that simultaneously targeting two of their major transcriptional regulators, p53 and c-Myc, may facilitate their eradication.

Publication types

  • Comment

MeSH terms

  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive*
  • Leukemia, Myeloid, Acute
  • Neoplastic Stem Cells*